A Retrospective Observational Study on Clinicopathological Features, Optimal Management and Recurrence Patterns in Low-Grade Endometrial Stromal Sarcoma
Purpose To evaluate the clinicopathological features, the role of neo-adjuvant and adjuvant treatment and recurrence patterns in patients with low-grade endometrial stromal sarcomas (LGESS). Materials and Methods Medical records of LGESS patients treated at gynec oncologic referral center between January 1, 2014, and October 31, 2021, were retrospectively reviewed. Statistical Analysis Recurrence-free survival (RFS) was calculated using the Kaplan–Meier method. Differences between survival curves were assessed using the log-rank test. Results A total of 21 consecutive patients with LGESS were identified. The mean age of presentation was 44.3 years (standard deviation of 10.26). The most common presenting complaint was abnormal uterine bleeding in 10 (47.6%) of 21 patients. Fourteen (67%) of 21 patients belonged to FIGO stage I and II. The mainstay of the treatment was total hysterectomy with bilateral salpingo-oophorectomy in all the 21 patients. Three (14.2%) patients with clinically and radiologically inoperable disease, started on neo-adjuvant hormone treatment for 8 weeks, underwent cytoreductive surgery with no residual disease. Recurrence-free survival (RFS) in the observation group of LGESS following surgery was 28 months while the RFS was 40 months if any adjuvant treatment was offered after surgery. Conclusion The cornerstone of management remains total hysterectomy with bilateral salpingo-oophorectomy. The use of neo-adjuvant hormone therapy in LGESS is strongly advocated in cases where it is deemed clinically and radiologically inoperable..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Indian Journal of Gynecologic Oncology - 21(2023), 4 vom: 16. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdul Shukur, Remi [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Hormones |
|---|
| Anmerkungen: |
© The Author(s) under exclusive licence to Association of Gynecologic Oncologists of India 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s40944-023-00759-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053770013 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053770013 | ||
| 003 | DE-627 | ||
| 005 | 20231215064719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231117s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40944-023-00759-9 |2 doi | |
| 035 | |a (DE-627)SPR053770013 | ||
| 035 | |a (SPR)s40944-023-00759-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdul Shukur, Remi |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Retrospective Observational Study on Clinicopathological Features, Optimal Management and Recurrence Patterns in Low-Grade Endometrial Stromal Sarcoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) under exclusive licence to Association of Gynecologic Oncologists of India 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose To evaluate the clinicopathological features, the role of neo-adjuvant and adjuvant treatment and recurrence patterns in patients with low-grade endometrial stromal sarcomas (LGESS). Materials and Methods Medical records of LGESS patients treated at gynec oncologic referral center between January 1, 2014, and October 31, 2021, were retrospectively reviewed. Statistical Analysis Recurrence-free survival (RFS) was calculated using the Kaplan–Meier method. Differences between survival curves were assessed using the log-rank test. Results A total of 21 consecutive patients with LGESS were identified. The mean age of presentation was 44.3 years (standard deviation of 10.26). The most common presenting complaint was abnormal uterine bleeding in 10 (47.6%) of 21 patients. Fourteen (67%) of 21 patients belonged to FIGO stage I and II. The mainstay of the treatment was total hysterectomy with bilateral salpingo-oophorectomy in all the 21 patients. Three (14.2%) patients with clinically and radiologically inoperable disease, started on neo-adjuvant hormone treatment for 8 weeks, underwent cytoreductive surgery with no residual disease. Recurrence-free survival (RFS) in the observation group of LGESS following surgery was 28 months while the RFS was 40 months if any adjuvant treatment was offered after surgery. Conclusion The cornerstone of management remains total hysterectomy with bilateral salpingo-oophorectomy. The use of neo-adjuvant hormone therapy in LGESS is strongly advocated in cases where it is deemed clinically and radiologically inoperable. | ||
| 650 | 4 | |a Hysterectomy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hormones |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neo-adjuvant therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Salpingo-oophorectomy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sarcoma–endometrial stromal |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Patel, Bijal M. |0 (orcid)0000-0002-5446-1959 |4 aut | |
| 700 | 1 | |a Dave, Pariseema |4 aut | |
| 700 | 1 | |a Patel, Shilpa M. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Journal of Gynecologic Oncology |d New Delhi : Springer India, 2015 |g 21(2023), 4 vom: 16. Nov. |w (DE-627)SPR037996819 |w (DE-600)2823586-1 |x 2363-8400 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:4 |g day:16 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40944-023-00759-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 4 |b 16 |c 11 | ||